Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Michael, Schaefers"'
Autor:
Clemens Kratochwil, Horacio Amaral, Camilo Sandoval, Frederik L. Giesel, Markus Hohenfellner, Katharina Sprute, M. Eiber, Norio Nonomura, Sadahiro Naka, Manuel Meneses, Jun Hatazawa, Viktoria Schütz, Tim Holland-Letz, Michael Schaefers, P. L. Choyke, Uwe Haberkorn, Juergen Debus, Cristian Soza-Ried, René Fernández, Vasko Kramer, Tadashi Watabe, Constantin Schwab, Kambiz Rahbar, Motohide Uemura, Isabel Rauscher, Stefan A. Koerber, Wolfgang Weber
Publikováno v:
Journal of Nuclear Medicine. 62:208-213
Prostate-specific membrane antigen (PSMA)-ligand PET/CT is performed on patients with prostate cancer to stage the disease initially or to identify sites of recurrence after definitive therapy. On the basis of clinical results, 18F-PSMA-1007 is a pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fa5b9e7bc98ca36a99c920746608219
https://doi.org/10.2967/jnumed.120.246363
https://doi.org/10.2967/jnumed.120.246363
Autor:
Maximilian Wiesmann, Cristina Barca, Amanda J. Kiliaan, Claudia Foray, Lydia Wachsmuth, Michael Schaefers, Sven Hermann, Bastian Zinnhardt, Cornelius Faber, Andreas H. Jacobs
Publikováno v:
The Journal of Nuclear Medicine (1978), 63, 446-452
The Journal of Nuclear Medicine (1978), 63, 3, pp. 446-452
The Journal of Nuclear Medicine (1978), 63, 3, pp. 446-452
Microglia-induced neuroinflammation after stroke contributes to the exacerbation of post-ischemic damage but also supports neurorestorative events. Longitudinal molecular imaging of microglia-targeted therapies will support the assessment of target e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b1b297c2ea17b420a03b2d854764d97
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/247898
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/247898
Autor:
Katharina, Sprute, Vasko, Kramer, Stefan A, Koerber, Manuel, Meneses, Rene, Fernandez, Cristian, Soza-Ried, Mathias, Eiber, Wolfgang A, Weber, Isabel, Rauscher, Kambiz, Rahbar, Michael, Schaefers, Tadashi, Watabe, Motohide, Uemura, Sadahiro, Naka, Norio, Nonomura, Jun, Hatazawa, Constantin, Schwab, Viktoria, Schütz, Markus, Hohenfellner, Tim, Holland-Letz, Juergen, Debus, Clemens, Kratochwil, Horacio, Amaral, Pete L, Choyke, Uwe, Haberkorn, Camilo, Sandoval, Frederik L, Giesel
Publikováno v:
Journal of Nuclear Medicine
Prostate-specific membrane antigen (PSMA)–ligand PET/CT is performed on patients with prostate cancer to stage the disease initially or to identify sites of recurrence after definitive therapy. On the basis of clinical results, 18F-PSMA-1007 is a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6af89fc847a0ff8a1750b1de011a9c32
https://pubmed.ncbi.nlm.nih.gov/32817141
https://pubmed.ncbi.nlm.nih.gov/32817141
Autor:
Klaas Nicolay, Jeanine J. Prompers, Sven Hermann, Michael T. Kuhlmann, Verena Hoerr, Philipp Bovenkamp, Desiree Abdurrachim, Jolita Ciapaite, Ilvy M. E. Geraets, Joost J. F. P. Luiken, Cornelius Faber, Michael Schaefers, Jan F. C. Glatz, Miranda Nabben, Will A. Coumans
Publikováno v:
Cardiovascular Research, 113(10), 1148-1160. Oxford University Press
Aims Heart failure is associated with altered myocardial substrate metabolism and impaired cardiac energetics. Comorbidities like diabetes may influence the metabolic adaptations during heart failure development. We quantified to what extent changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95726af092d8d547ae3f6030178b5fba
https://doi.org/10.1093/cvr/cvx100
https://doi.org/10.1093/cvr/cvx100
Autor:
Tobias Maier, Michael Schaefers, Joachim Gerß, Otmar Schober, Alexis Vrachimis, Burkhard Riemann, Christian Wenning, Dennis Görlich
Publikováno v:
Journal of Nuclear Medicine. 56:190-195
The aim of this study was to compare the overall survival of a large, single-center cohort of patients who had differentiated thyroid cancer (DTC) with that of a matched general population.We analyzed 2,428 consecutive patients who had DTC and underw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf8819fad9aeef8be4c0df7f03fb3bc0
https://doi.org/10.2967/jnumed.114.150284
https://doi.org/10.2967/jnumed.114.150284
Autor:
Fabian Maximilian Meinert, Axel Florschütz, Ulrich Kaiser, Thomas Edelmann, Christian Junghanß, Michael Schaefers, Bert Hildebrandt, Thomas Göhler, Jörg Steighardt, Stephan Kanzler, Carla Hannig, Arndt Vogel, Alexander Stein, Heinz-Gert Hoeffkes, Hans-Joachim Schmoll, Jörn Rüssel, Benjamin Garlipp, Franziska Cygon, Helmut Forstbauer, Malte Leithäuser
Publikováno v:
Annals of Oncology. 28:iii152
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80c7742d220696d2adf7ad6e903ef8e0
https://doi.org/10.1093/annonc/mdx302.006
https://doi.org/10.1093/annonc/mdx302.006
Autor:
Hans-Joachim Schmoll, Bert Hildebrandt, Stephan Kanzler, Ulrich Kaiser, Axel Florschütz, Jörg Steighardt, Alexander Stein, Heinz-Gert Hoeffkes, Thomas Edelmann, Michael Schaefers, Thomas Goehler, Carla Hannig, Fabian Maximilian Meinert, Arndt Vogel, Franziska Cygon, Helmut Forstbauer, Malte Leithäuser, Jörn Rüssel, Christian Junghanss, Benjamin Garlipp
Publikováno v:
Journal of Clinical Oncology. 35:3533-3533
3533 Background: FOLFOXIRI/Bevacizumab (Bev) is superior to FOLFIRI/Bev in the TRIBE trial (F Loupakis, NEJM 2014). The CHARTA trial was developed parallel to TRIBE with the same 4-drug-protocol but vs. FOLFOX/B ev as control arm. Methods: From 7/11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aca22bdd32d1fb1a606446b72ca3fafb
https://doi.org/10.1200/jco.2017.35.15_suppl.3533
https://doi.org/10.1200/jco.2017.35.15_suppl.3533
Autor:
Stephan Kanzler, Christian Junghanss, Ulrich Kaiser, Bert Hildebrandt, Thomas Edelmann, Alexander Stein, Carsten Bokemeyer, Benjamin Garlipp, Axel Florschütz, Jörg Steighardt, Malte Leithaeuser, Thomas Goehler, Heinz-Gert Hoeffkes, Michael Schaefers, Jörn Rüssel, Hans-Joachim Schmoll, Helmut Forstbauer, Carla Hannig, Arndt Vogel, Julia Quidde
Publikováno v:
Journal of Clinical Oncology. 35:3544-3544
3544 Background: FOLFOXIRI/bev is a highly efficacious first line regimen in MCRC. Despite higher rates of neutropenia, diarrhea and stomatitis, FOLFOXIRI/bev is tolerable and feasible in MCRC patients. To date nothing is known about the impact of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d85ce134f39c7bb977300114b07ebe7
https://doi.org/10.1200/jco.2017.35.15_suppl.3544
https://doi.org/10.1200/jco.2017.35.15_suppl.3544
Autor:
Fabian Maximilian Meinert, Christian Junghanss, Carla Hannig, Malte Leithaeuser, Stephan Kanzler, Axel Florschütz, Thomas Goehler, Thomas Edelmann, Franziska Cygon, Helmut Forstbauer, Bert Hildebrandt, Jörg Steighardt, Heinz-Gert Hoeffkes, Michael Schaefers, Hans-Joachim Schmoll, Benjamin Garlipp, Alexander Stein, Jörn Rüssel, Arndt Vogel, Ulrich Kaiser
Publikováno v:
Journal of Clinical Oncology. 35:658-658
658 Background: The 4-drug-regimen FOLFOXIRI+Bevacizumab (Bev) was superior to FOLFIRI+Bev (TRIBE F.Loupakis, NEJM 2014). CHARTA investigates the same 4-drug-regimen vs. FOLFOX+Bev. Methods: 250 patients were randomized from 7/11 to 12/14 to standard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e165aabf60d8e77a446ec36ab1ddd28
https://doi.org/10.1200/jco.2017.35.4_suppl.658
https://doi.org/10.1200/jco.2017.35.4_suppl.658
Autor:
Nemanja Avramovic, Michael Claesener, Axel Bode, Michael Schaefers, Lars Stegger, Kambiz Rahbar, Matthias Weckesser, Martin Boegemann
Publikováno v:
Journal of Clinical Oncology. 34:e16575-e16575
e16575Background: Despite several new treatment options in metastatic castration resistant prostate cancer (mPCa), especially in castration resistant PCa (mCRPC), eventual resistance to approved tr...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c52f43c9dc401d9ac38c33469969d7a
https://doi.org/10.1200/jco.2016.34.15_suppl.e16575
https://doi.org/10.1200/jco.2016.34.15_suppl.e16575